

BIND Biosciences, Inc. appoints Jim Wright, PhD as Chief Scientific Officer

CAMBRIDGE, MA – December 18, 2007 – BIND Biosciences, Inc. (BIND), a privately held biopharmaceutical company developing “smart” therapeutic targeted nanoparticles capable of controlled drug delivery to diseased tissue, announced today the appointment of Jim Wright, Ph.D., as Chief Scientific Officer.

“We are thrilled to have Jim join our team. He has led a distinguished career in pharmaceutical development and is widely recognized as a leader in the biotechnology field,” said Glenn Batchelder, President and Chief Executive Officer at BIND. He continued, “Jim is uniquely qualified to translate our platform into important therapies. He has a track record of success in developing and commercializing multiple drug modalities including products based on traditional dosage forms such as Viramune®, for treatment of HIV-1 infection, and on breakthrough drug delivery platforms, such as Risperdal Consta®, a long-acting injectable form of the antipsychotic risperidone.”

Dr. Wright said, “This is a tremendous opportunity to create a revolutionary new class of therapeutics through the technological convergence of controlled release polymer systems, targeted delivery and combinatorial nanoparticle optimization. I am delighted to join this talented and experienced team in working to fulfill the enormous potential of this technology platform.”

Dr. Wright was most recently Vice President of Development at Infinity Pharmaceuticals. Previously, he was Vice President of Pharmaceutical Development at Millennium Pharmaceuticals, Senior Vice President of Development at Alkermes and Distinguished Scientist at Boehringer Ingelheim Pharmaceuticals. Additionally, Dr. Wright teaches at the University of Wisconsin as an Adjunct Professor. Dr. Wright received his Ph.D. in Pharmacy from the University of Wisconsin and B.A. degrees in Biology and Chemistry from the University of California, Santa Barbara.

About BIND Biosciences, Inc.

BIND Biosciences is a privately held biopharmaceutical company focused on developing therapeutic targeted nanoparticles to concentrate drug at the intended site of action while minimizing systemic exposure, thereby improving efficacy and reducing off-target effects. The company’s platform is broadly applicable across therapeutic areas with the initial product development efforts focused in cancer and cardiovascular disease. The company anticipates initiating clinical trials for their first product in 2009.

BIND was founded in 2006 by two pioneers in the field of therapeutic targeted nanoparticles, Dr. Robert Langer, MIT Institute Professor, and Dr. Omid Farokhzad, Harvard Medical School Assistant Professor. The company licensed a large patent estate on a worldwide exclusive basis from MIT and Brigham and Women’s Hospital – Harvard Medical School covering the scientific founders’ work in targeted nanoparticle therapeutics. In 2007, BIND was the recipient of peer-reviewed awards from the National Institute of Standards and Technology’s Advanced Technology Program and the National Cancer Institute. The company has assembled a world-class management and scientific team drawn from companies such as Millennium Pharmaceuticals, Alkermes, Infinity Pharmaceuticals, Momenta, Acceleron Pharma, Boehringer Ingelheim Pharmaceuticals and Sepracor. BIND is backed by leading venture capital firms, Polaris Venture Partners, Flagship Ventures, ARCH Ventures and NanoDimension. For more information, please visit the company’s web site at www.bindbio.com.

Contacts

BIND Biosciences, Inc.

Glenn Batchelder, President and CEO

617-491-3400